Recent advances in the neuropathology of multiple sclerosis

Revue Neurologique

Volumn 163, Issue 6-7, 2007, Pages 657-661

  Stadelmann, C ^a  

^a Institute of Neuropathology   (Germany)

Author keywords

Axonal damage; Cortex; Demyelination; Multiple sclerosis; Remyelination

Indexed keywords

BRAIN DAMAGE; CLINICAL FEATURE; CONFERENCE PAPER; DEMYELINATION; HUMAN; INFLAMMATORY INFILTRATE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PHYSICAL DISABILITY; PREDICTION;

EID: 34347330031     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(07)90475-0     Document Type: Conference Paper

References (46)

1. ALBERT M, ANTEL J, BRUCK W, STADELMANN C. (2007). Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol, 17: 129-138.
2. BABBE H, ROERS A, WAISMAN A et al. (2000). Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med, 192: 393-404.
3. BARNETT MH, PRINEAS JN. (2004). Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol, 55: 458-468.
4. BEN NUN A, WEKERLE H, COHEN IR. (1981). The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol, 11: 195-199.
5. BITSCH A, SCHUCHARDT J, BUNKOWSKI S, KUHLMANN T, BRUCK W. (2000). Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain, 123 (Pt 6): 1174-1183.
6. BO L, VEDELER CA, NYLAND H, TRAPP BD, MORK SJ. (2003b). Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler, 9: 323-331.
7. BO L, VEDELER CA, NYLAND HI, TRAPP BD, MORK SJ. (2003a). Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol; 62: 723-732.
8. BRUCK W, NEUBERT K, BERGER T, WEBER JR. (2001). Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination - possible markers for an antibody-mediated process. Mult Scler, 7: 173-177.
9. BRUCK W, PORADA P, POSER S et al. (1995). Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol, 38: 788-796.
10. CHANG A, TOURTELLOTTE WW, RUDICK R, TRAPP BD. (2002). Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med, 346: 165-173.
11. e ed. Paris.
12. CIFELLI A, ARRIDGE M, JEZZARD P, ESIRI MM, PALACE J, MATTHEWS PM. (2002). Thalamic neurodegeneration in multiple sclerosis. Ann Neurol, 52: 650-653.
13. DE STEFANO N, MATTHEWS PM, ANTEL JP, PREUL M, FRANCIS G, ARNOLD DL. (1995). Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol, 38: 901-909.
14. DUTTA R, MCDONOUGH J, YIN X et al. (2006). Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol, 59: 478-489.
15. FERGUSON B, MATYSZAK MK, ESIRI MM, PERRY VH. (1997). Axonal damage in acute multiple sclerosis lesions. Brain, 120(Pt 3): 393-399.
16. FRANKLIN RJ. (2002). Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci, 3: 705-714.
17. GENAIN CP, CANNELLA B, HAUSER SL, RAINE CS. (1999). Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med, 5: 170-175.
18. HEMMER B, NESSLER S, ZHOU D, KIESEIER B, HARTUNG HP. (2006). Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol, 2: 201-211.
19. KEEGAN M, KONIG F, MCCLELLAND R et al. (2005). Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, 366: 579-582.
20. KERSCHENSTEINER M, SCHWAB ME, LICHTMAN JW, MISGELD T. (2005). In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat Med, 11: 572-577.
21. KRUMBHOLZ M, THEIL D, DERFUSS T et al. (2005). BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med, 201: 195-200.
22. KUHLMANN T, LINGFELD G, BITSCH A, SCHUCHARDT J, BRUCK W. (2002). Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain, 125: 2202-2212.
23. KUTZELNIGG A, LUCCHINETTI CF, STADELMANN C et al. (2005). Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain, 128: 2705-2712.
24. LENNON VA, KRYZER TJ, PITTOCK SJ, VERKMAN AS, HINSON SR. (2005). IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med, 202: 473-477.
25. LININGTON C, BRADL M, LASSMANN H, BRUNNER C, VASS K. (1988). Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol, 130: 443-454.
26. LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H. (1999). A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain, 122 (Pt 12): 2279-2295.
27. LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol, 47: 707-717.
28. LUCCHINETTI CF, BRUCK W, LASSMANN H. (2004). Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol, 56: 308.
29. MARBURG O. (1906). Die sogenannte "akute multiple Sklerose" (Encephalomyelitis peraxialis scleroticans). Jahrb Neurol Psych, 27: 211-312.
30. MARBURG I, MARTINIC MA, WEKERLE H, NEUMANN H. (2001). Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol, 159: 809-815.
31. MERKLER D, BOSCKE R, SCHMELTING B et al. (2006a). Differential Macrophage/Microglia Activation in Neocortical EAE Lesions in the Marmoset Monkey. Brain Pathol, 16: 117-123.
32. MERKLER D, ERNSTING T, KERSCHENSTEINER M, BRUCK W, STADELMANN C. (2006b). A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain, 129(Pt 8): 1972-1983.
33. METZ I, LUCCHINETTI CF, OPENSHAW H et al. (2007). Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain, 130: 1254-62.
34. MISGELD T, KERSCHENSTEINER M. (2006). In vivo imaging of the diseased nervous system. Nat Rev Neurosci, 7: 449-463.
35. NARAYANAN S, DE STEFANO N, FRANCIS GS et al. (2001). Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol, 248: 979-986.
36. O'CONNOR KC, APPEL H, BREGOLI L et al. (2005). Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol, 175: 1974-1982.
37. PATRIKIOS P, STADELMANN C, KUTZELNIGG A et al. (2006). Remyelination is extensive in a subset of multiple sclerosis patients. Brain, 129: 3165-3172.
38. PETERSON JW, BO L, MORK S, CHANG A, TRAPP BD. (2001). Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol, 50: 389-400.
39. PRINEAS JW. (1985). The neuropathology of multiple sclerosis. In: Koetsier, editor. Demyelinating Diseases. Amsterdam: p. 337-98.
40. PRINEAS JW, BARNARD RO, KWON EE, SHARER LR, CHO ES. (1993). Multiple sclerosis: remyelination of nascent lesions. Ann Neurol, 33: 137-151.
41. SERAFINI B, ROSICARELLI B, MAGLIOZZI R, STIGLIANO E, ALOISI F. (2004). Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol, 14: 164-174.
42. TRAUGOTT U, REINHERZ EL, RAINE CS. (1983). Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science, 219: 308-310.
43. VAN WAESBERGHE JH, KAMPHORST W, DE GROOT CJ et al. (1999). Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol, 46: 747-754.
44. VERCELLINO M, PLANO F, VOTTA B, MUTANI R, GIORDANA MT, CAVALLA P. (2005). Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol, 64: 1101-1107.
45. WEGNER C, ESIRI MM, CHANCE SA, PALACE J, MATTHEWS PM. (2006). Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology, 67: 960-967.
46. ZHOU D, SRIVASTAVA R, NESSLER S et al. (2006). Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA, 103: 19057-19062.